The recently developed receptor agonists for glucagon-like peptide-1 (GLP-1RAs), stimulate insulin secretion and reduce glycated hemoglobin levels without having side effects such as weight gain and hypoglycemia
Average pulse rate increased by 3.7 bpm and 4.7 bpm with orforglipron 12 mg and 36 mg doses respectively
Oxidative stress and cancer
These model-based results are consistent with the noncompartmental results for trial 7 (see Table S1 in the ESM), in which equivalence was demonstrated for exposure (AUC 0 ) for all pairwise comparisons between the three strengths of semaglutide
Does it have as many benefits as we expect
Smoking, hypertension, high cholesterol, diabetes, physical inactivity, obesity, and an unhealthy dietary pattern remain among the most important modifiable heart-disease risk factors